Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The £13m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec supported 12 new projects in first year of operation.

Thomas hanke.jpg
Thomas Hanke, Expert-in-Residence at Evotec

LAB282, the £13m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec, is celebrating its first year of operation after successfully accelerating 12 drug discovery and development projects at the University.

In total, the partnership has provided 14 awards, both small and large scale.

In its fourth and latest round of awards, LAB282 backed the following Oxford projects:

  • Validation of novel targets for myelofibrosis, a severe bone marrow disorder.
  • Development of glucosidase II interface inhibitors; towards a novel class of broad-spectrum antivirals.
  • Discovery of potent inhibitors to DarG antitoxins as a first-in-class anti-microbial concept.
  • Advancing the development of evasins, a novel class of chemokine-trap to treat inflammatory disorders.

Find out more (Oxford University Innovation website)